



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/502,283	08/01/2005	Bruce Verchere	07891/032002	9175
21559 CLARK & ELI	7590 02/21/2003 BING LLP	8	EXAMINER	
101 FEDERAL	STREET		EPPS FORD, JANET L	
BOSTON, MA	X 02110		ART UNIT	PAPER NUMBER
			1633	
			NOTIFICATION DATE	DELIVERY MODE
			02/21/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentadministrator@clarkelbing.com

		Application No.	Applicant(s)		
· ·		10/502,283	VERCHERE ET AL.		
Office Act	tion Summary	Examiner	Art Unit		
		Janet L. Epps-Ford	1633		
The MAILING I	DATE of this communication app	ears on the cover sheet with the	correspondence address		
WHICHEVER IS LON - Extensions of time may be a after SIX (6) MONTHS from - If NO period for reply is spe - Failure to reply within the se	TUTORY PERIOD FOR REPLY IGER, FROM THE MAILING DA available under the provisions of 37 CFR 1.13 the mailing date of this communication. cified above, the maximum statutory period wet or extended period for reply will, by statute, iffice later than three months after the mailing ent. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be to the second will expire SIX (6) MONTHS from the cause the application to become ABANDON	N. imely filed n the mailing date of this communication. ED (35 U.S.C. § 133).		
Status					
1) Responsive to	communication(s) filed on <u>01 Au</u>	<u>igust 2005</u> .			
2a) ☐ This action is F	This action is FINAL . 2b)⊠ This action is non-final.				
•	 · · ·				
closed in accor	dance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	l53 O.G. 213.		
Disposition of Claims					
4a) Of the above 5) ☐ Claim(s) 6) ☐ Claim(s) 7) ☐ Claim(s)	is/are rejected.	vn from consideration.	n requirement.		
Application Papers					
9) The specification	n is objected to by the Examiner	·.			
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
,,	ot request that any objection to the o	*			
	wing sheet(s) including the correctill laration is objected to by the Ex				
Priority under 35 U.S.C.	§ 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s)	od (PTO 892)	4) 🔲 Interview Summar	v (PTO-413)		
 Notice of References Cite Notice of Draftsperson's Information Disclosure Straper No(s)/Mail Date 	Patent Drawing Review (PTO-948) tatement(s) (PTO/SB/08)	4) Interview Summar Paper No(s)/Mail [5) Notice of Informal 6) Other:	Date		

10/502,283 Art Unit: 1633

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-3, 6-7, 9-23, 54-56, and 67-68 drawn to a method treating diabetes in a subject in need comprising providing cells to patient that express a transgene encoding IAP polypeptide.

Group II, claim(s) 1-3, 6-7, 9-23, 54-56, and 67-68 drawn to a method treating diabetes in a subject in need comprising providing cells to patient that express a transgene encoding a fragment of IAP polypeptide.

Group III, claim(s) 63, 66, and 69, drawn to cells and a medicament comprising said cells capable of expressing insulin, wherein said cells express a transgene encoding an IAP polypeptide.

Group IV, claim(s) 63-66, and 69, drawn to cells and a medicament comprising said cells capable of expressing insulin, wherein said cells express a transgene encoding a fragment of an IAP polypeptide.

2. The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The instant claims are drawn to multiple methods and multiple products, and are therefore considered to read on more than one category of invention. As per 37 CFR § 1.475(c) if an application contains more than one category of invention as set forth in 1.475(b), unity of invention might not be present. In the instant case, the claims are directed to multiple products, and a method of producing one of these products. It is therefore concluded that the claims are directed to multiple categories of invention, and therefore unity of invention is not present.

§ 1.475 Unity of invention before the International Searching Authority, the

10/502,283 Art Unit: 1633

International Preliminary Examining Authority and during the national stage.

- (a) An international and a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention"). Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.
- (b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:
- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.
- (c) If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present.
- (d) If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each of the other categories related thereto will be considered as the main invention in the claims, see PCT Article 17(3)(a) and § 1.476(c).
- (e) The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.
- 3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Claims 6-7 recites multiple promoters that require a separate search and consideration of the prior art.

Claims 14-20 recite a plurality of different cell types for use in the methods of the claimed invention.

10/502,283

Art Unit: 1633

Claim 21-22 recite multiple organs wherein transplantation is intended according

to the recited methods.

Applicant is required, in reply to this action, to elect a single species of promoter

from claims 6-7, a single species of cell type from claims 14-20, and a single species of

organ from claims 21-22, to which the claims shall be restricted if no generic claim is

finally held to be allowable. The reply must also identify the claims readable on the

elected species, including any claims subsequently added. An argument that a claim is

allowable or that all claims are generic is considered non-responsive unless

accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration

of claims to additional species which are written in dependent form or otherwise include

all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims

are added after the election, applicant must indicate which are readable upon the

elected species. MPEP § 809.02(a).

4. The claims are deemed to correspond to the species listed above in the following

manner:

See above

The following claim(s) are generic: 1-2, 9-13, 23, 54-56, and 63-69 are generic with

respect to the species set forth above.

5. The species listed above do not relate to a single general inventive concept

under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or

corresponding special technical features for the following reasons:.

Art Unit: 1633

- (a) When the Markush grouping is for alternatives of chemical compounds, they are regarded as being of a similar nature where the following criteria are fulfilled:
 - all alternatives have a common property or activity, and (A)
 - a common structure is present, that is, a significant structural element is shared by all of the alternatives, or
 - (B)(2) in cases where the common structure cannot be the unifying criteria, all alternatives belong to a recognized class of chemical compounds in the art to which the invention pertains.
- 6. In the instant case, the multiple promoters recited in the instant claims comprise a distinct nucleotide sequence, and therefore do not share a common structural element.
- 7. In regards to the differences in cells and organs recited in the instant claims, the distinct cells types and organs are distinct in their source and function, and are therefore considered to lack unity of invention.
- 8. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of

10/502,283 Art Unit: 1633 Page 6

record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions

unpatentable over the prior art, the evidence or admission may be used in a rejection

under 35 U.S.C.103(a) of the other invention.

9. Applicant is reminded that upon the cancellation of claims to a non-elected

invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by

a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

10/502,283 Art Unit: 1633

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Epps-Ford whose telephone number is 571-272-0757. The examiner can normally be reached on M-F, 10:00 AM through 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Janet L. Epps-Ford/ Primary Examiner Art Unit 1633